Neuralink says 12 people have received its brain implants as trials expand; company tests tech to help people with paralysis
Neuralink says 12 people worldwide have received its brain implants, enabling some with severe paralysis to control digital devices with their thoughts as the company expands the FDA-authorized PRIME study to evaluate safety and efficacy.
- Neuralink reports that 12 people have received its brain implants worldwide as part of ongoing clinical testing
- Devices aim to help people with severe paralysis control digital devices using brain signals
- The PRIME study is Neuralink’s main FDA-authorized human trial
How the Neuralink device works
Neuralink’s brain-computer interface (BCI) uses ultra-thin electrode “threads” to read brain activity in areas that plan movement. A compact implant sits on the skull and transmits signals wirelessly to a computer. Neural signals are decoded and translated into commands that move an on-screen cursor or operate apps, enabling users to control devices without physical movement — detailed in NPR Illinois’ overview.
The threads are extremely fine — roughly 10–12 microns at the tip, about the width of a red blood cell. Neuralink uses a robotic system to place these threads into the cortex with high precision; the robot is designed to limit tissue damage and make the procedure less invasive than older implants — see NPR Illinois.
Clinical progress and early user experiences
The first human implant occurred in early 2024. Since then, Neuralink says it has increased recipients to 12 as of mid-2025 — a rapid rise from the initial handful of participants (NPR Illinois; TechSpot).
Users and performance: Most recipients remain anonymous, though some, like Noland Arbaugh (paralyzed after a swimming accident), have described using the device to play chess and video games, browse the web and manage email by thought alone — reported by Observer and CGTN.
Some recipients have reportedly achieved high control accuracy — in some cases around 90% — for on-screen cursor movement and task completion, suggesting potential for restoring professional-level function (CGTN; Observer).
Technical hurdles and adjustments
Neuralink has documented issues and iterated quickly. One notable problem was thread retraction — tiny electrodes shifting away from their original positions, which degraded signal quality. The company adjusted implantation depth and updated software to improve decoding and long-term stability (Observer).
Experts in the BCI field warn that long-term performance hinges on how brain tissue responds over months and years. Biocompatibility and recording stability remain central concerns. While the robot and ultra-thin threads aim to reduce tissue damage, independent long-term data are limited (peer-reviewed analysis).
Regulatory and ethical context
Neuralink received FDA authorization to begin human trials in May 2023. Its PRIME study (Precise Robotically Implanted Brain-Computer Interface) is the declared main trial to assess safety and performance in people with paralysis — NPR Illinois.
“Early trial results should be viewed with caution: tightly controlled settings and careful follow-up do not yet reflect broader clinical use.”
As trials scale, questions around patient selection, informed consent and long-term monitoring intensify. Full regulatory approval for general medical use will require extensive evidence of safety and benefit over time (see analysis).
Competition and the broader research landscape
Neuralink is among multiple groups developing implantable BCIs at universities and private companies. What distinguishes Neuralink is its rapid pace and integrated approach — combining robotics, ultra-thin electrodes and wireless systems — plus a high public profile tied to Elon Musk. Independent peer-reviewed comparisons remain limited (CGTN; peer-reviewed analysis).
Company goals and growth targets
Neuralink’s leadership has signaled aggressive trial expansion. Musk and company statements in early 2025 mentioned a goal of placing 20–30 implants by year-end, underscoring a push to scale PRIME study enrollment and gather usability, risk and real-world performance data (Observer).
Sources and reporting
This article draws on reporting and commentary from multiple outlets and scientific literature, including TechSpot, NPR Illinois, CGTN, Observer, and peer-reviewed discussion of BCI safety and ethics.
Implications for Los Angeles, California
Neuralink’s progress could have multiple local impacts across economics, politics, society and healthcare in Los Angeles. Below are key dimensions to watch as trials expand.
Economic impact
Progress may spur investment and jobs in Southern California’s tech and medical sectors. Hospitals and clinics could see new trial roles, device manufacturing contracts and research partnerships, creating positions in engineering, clinical research, nursing and rehabilitation services.
Political consequences
Local and state officials may need to balance innovation incentives with oversight of patient safety. Policymakers could be asked to clarify data privacy, consent standards and whether public institutions should host trials.
Social effects
For Angelenos with paralysis, BCI devices offer new hope. Access will initially be limited to trial participants who meet strict criteria; equity concerns (cost, insurance, trial locations) are likely to drive advocacy for fair access.
Cultural relevance
Los Angeles’ mix of tech enthusiasm and demand for accountability means the Neuralink story will be closely scrutinized by local media, academic centers and patient groups demanding transparent reporting and long-term data.
Practical applications and daily life
If proven safe and effective, BCIs could restore daily functions — typing, smartphone control, smart-home operation and work tasks — and change caregiving needs by increasing patient independence.
Healthcare system readiness
LA hospitals may need surgical teams skilled with robotic implants, specialized follow-up clinics, and interdisciplinary teams (neurologists, neurosurgeons, rehab specialists, bioethicists) to support local trial participation.
Legal and privacy considerations
BCIs raise complex questions about data ownership and privacy. Neural signals are deeply personal; legal and healthcare stakeholders in LA will likely push for clear rules on access, storage and use of neural data.
Research and academic collaboration
LA universities and research centers could contribute independent outcome evaluations, equitable trial recruitment design and long-term effect studies, working alongside companies to inform regulators and the public.
End of substantive reporting on Neuralink’s reported expansion to 12 human recipients and the local implications for Los Angeles, California.
